Joshua Waitzman, MD PhD Swapnil Hiremath @[email protected] Many might be surprised with the mild effect of pantoprazole to prevent GI bleeds in the COMPASS trial pubmed.ncbi.nlm.nih.gov/31054846/

Hi everyone! Pallavi here from New Delhi , no COI #NephJc

Compass trial rate of eGFR decline difference between PPI vs no PPI arm in patients with a mean eGFR 75 ml/min was 0.27 ml/min/yr or 20% #NephJC

Nephrology Journal Club Indeed. The existent evidence, databases and observational studies show a much higher CKD prevalence - lots of possible confounders, concomitant medications etc #nephjc

Once deprescribing eligibility is established, a strategy that tapers PPI use is recommended. Abrupt PPI discontinuation could potentially result in rebound symptoms of acid hypersecretion. It is suggested to ⬇️ PPI dose by 50% in 1- to 2-week intervals. #NephJC

M wondering if semaglutide is going to increase our PPI use? What do people who have experience with sema say about this? Double edged sword? 🗡️#NephJc 😲

Welcome to #TenTweetNephJC ✳️10 tweets #NephJC catch-up ✳️ Nephrologists cringe when we see PPI on the med list, but how bad are these ubiquitous drugs, really? We review post-hoc analysis of the COMPASS trial (which collected PPI use data) designed to answer this question.

Teaching C1q in glomeruli on immunofluorescence microscopy. My experience is if + it is real & is not non specific. Positive: 1. Autoimmune disease=always + 2. Monoclonal Ig (PGNMID/MIDD)=often + 3. Infections= can be + or - Negative: 1.IgA nephropathy 2.C3 glomerulopathy

🎯Tonight we'll activate our #NephJC radars to learn more about rare kidney disease ⏰Chat 1 9pm EST, July 10 ⏰Chat 2 9pmIST/ 3:30pm GMT, July 11 ✨Hope see the authors RaDaR Prof Danny Gale Jonathan Barratt David Kavanagh kate bramham 🔗@Lancet article pubmed.ncbi.nlm.nih.gov/38492578/

⏩Next #NephJC 9 pm EST July 23rd, and 9 pm IST 24th July 🎁Kidney donation is a gift, but is there a price for the donor? ✍️Summary by Manish Lalwani Sejal Lakhani, DO nephjc.com/news/donors-hy…

Remember that living kidney donation is the best kidney failure treatment we have #NephJC will discuss JAMA article on kidney donation risks by Amit Garg and co #Visualabstract by Manish Lalwani

Hi everyone 👋#NephJC Pallavi from New Delhi, lurking today morning...will join tonight for Asian chat.

Check out this great VA I Manish Lalwani created for my #NephJC session during my Neal Shah internship. Don’t miss it!

T0b Human kidneys don’t grow on trees (or pigs, yet) so physicians have a responsibility to the donor as the recipient! Donors should be well informed of risks I’ve summarized some perioperative complications for kidney donors. Neal Shah #NephJC@manishmedicine1 Neal Shah #NephJC

T0e Unfortunately, the literature on the long term outcomes of LKD is not robust. Published studies vary in methodology, sample size, follow-up duration and control group selection. More data is needed to be able to adequately discuss the risks with potential donors. #NephJC

T0h Here is a donor risk calculator that estimates long-term ESKD risk using a given set of demographic and baseline (pre-donation) health characteristics regardless of any added risk after nephrectomy. Have you ever used this tool? #NephJC transplantmodels.com/esrdrisk/

Long term outcomes of love kidney donation #NephJC

T2g Should living kidney donors be categorized as having CKD II with similar associated health risks due to the decline in GFR?

#NephJC interesting study mentioning low mGFR as most important cause of rejection of donors. journals.lww.com/ijjt/fulltext/…

Hi everyone! Super late to #nephjc. But managed to finish the book late last night ☺️😴🥱